Latest news

• Roche’s spinal muscular atrophy therapy Evrysdi approved by EC for newborns

  Evrysdi (risdiplam), which is already authorised for use in patients aged two months or older, can now be used to treat infants from birth to below two months with a clinical

• New NHS treatments increase survival rates for babies with spinal muscular atrophy

  The new findings follow the recent roll-out of three new SMA medicines provided on the NHS: injectable drug Spinraza (nurinersen), gene therapy Zolgensma and oral treatment risdiplam, as well as

• Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

  The Committee for Medicinal Products for Human Use (CHMP) has recommended that the existing EU marketing authorisation for Evrysdi (risdiplam), which is approved to treat patients aged two months or older,

• Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

  Roche has announced positive new four-year results from an open-label extension study of its spinal muscular atrophy (SMA) treatment, Evrysdi (risdiplam), in young children.

• Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

  Genentech – a member of the Roche group – has announced new two-year data from its JEWELFISH study evaluating Evrysdi (risdiplam) in patients with type 1, 2 or 3 spinal muscular atrophy